Deals Of The Week: Wondering Where Have The Private Biotech Take-Outs Gone?
M&A has slowed for private biotechs this year, as acquisitions are overshadowed by IPOs. AstraZeneca is one of the few big biopharmas actively buying private biotechs. An option-to-acquire deal structure, amply employed by Celgene, is popping up lately.
You may also be interested in...
The largest dedicated health care investor has closed a huge new fund, which came almost entirely from existing investors. OrbiMed isn’t the only firm capitalizing on the robust biotech IPO market. A few VCs are starting to take gains from IPO winners through secondary offerings.
Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.